Advitech Inc. ("Advitech" or the "Company") (TSX Venture Exchange: AVI) announces today a distribution agreement with PL Thomas & Co., Inc. ("PLT") for the sale and marketing of its ingredient XP-828L for the United States market.
Advitech and PLT, a major U.S. distributor of active ingredients for nutraceutical, cosmeceutical and functional foods industries, have concluded a non-exclusive distribution agreement with a yearly commitment for Advitech's XP-828L ingredient, a patent-pending composition consisting of growth factors, especially TGF- B2, capable to maintain healthy cytokines levels and to support inflammatory process.
"The agreement with PLT is significant as it is an important player in several segments of the American market targeted by Advitech" stated Mr. Luc Clouâtre, Vice-President Business Development, Sales and Marketing at Advitech. Mr. Clouâtre further added, "PL Thomas has strong market visibility and existing business with many of the leading companies in the food and dietary supplements industry". PLT has an excellent understanding of the markets targeted by Advitech, and it will present the XP-828L to the U.S. market this week at the Supply Side West ("SSW") ingredients show. Product information will be displayed at the PLT booth, and Paul Flowerman, its President, will discuss this ingredient in his speech, an official part of the cosmeceutical track of the SSW educational program.
Other products of the Advitech portfolio, as well as several new innovations, could be added in the Advitech-PLT agreement upon further
ABOUT PL THOMAS http://www.plthomas.com:
PL Thomas, a New Jersey-based ingredients supplier, offers fifty years of innovation in internationally sourcing reliable, high quality raw materials
for the food and beverage, functional food, dietary supplements, and nutricosmetic industries. PLT is a one-stop resource for application solutions, current industry information and technical service, and specializing in branded and clinically supported natural ingredients, notably
ABOUT ADVITECH http://www.advitech.com/:
Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in inflammatory process by maintaining healthy cytokines levels. Advitech produces Dermylex(R) that helps reduce scaly and itchy skin and helps maintain healthy skin.
Advitech has drawn up a research program to develop new applications related to wound healing. This development is derived from both its XP-828L and IM technological platforms.
This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.